Ftse Mib
38.779,67
0,68%
DAX
23.419,48
1,30%
S&P 500
5.738,52
-1,78%
NASDAQ
18.069,26
-2,61%
Bitcoin
85.758,94
-4,66%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amneal Pharmaceuticals Inc (AMRX) Amneal Pharmaceuticals Inc (AMRX) Notizie

Amneal Pharmaceuticals Inc

AMRX
8,76
-0,21 (-2,34%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:30:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/3/202502:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202501:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202501:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202501:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202501:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202523:02EDGAR2Form 144 - Report of proposed sale of securities
05/3/202522:57EDGAR2Form 144 - Report of proposed sale of securities
05/3/202500:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202512:13EDGAR2Form 8-K - Current report
28/2/202512:00BWAmneal Reports Fourth Quarter and Full Year 2024 Financial..
19/2/202514:00BWAmneal Launches Mesalamine and Receives U.S. FDA Approval..
05/2/202522:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202514:30BWAmneal to Report Fourth Quarter and Full Year 2024 Results..
23/1/202523:49EDGAR2Form SCHEDULE 13D/A - General Statement of Acquisition of..
23/1/202514:00BWAmneal Receives U.S. FDA Approval for Memantine/Donepezil..
15/1/202512:14EDGAR2Form 8-K - Current report
10/1/202522:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202522:48EDGAR2Form 144 - Report of proposed sale of securities
04/12/202414:00BWAmneal to Participate at Upcoming Investor Conferences
26/11/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/11/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202416:39EDGAR2Form 144 - Report of proposed sale of securities
21/11/202422:05BWAmneal Resubmits DHE Autoinjector New Drug Application and..
21/11/202420:01EDGAR2Form 144 - Report of proposed sale of securities
19/11/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202419:49EDGAR2Form 144 - Report of proposed sale of securities
14/11/202422:11EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202422:25EDGAR2Form 8-K/A - Current report: [Amend]
08/11/202412:08EDGAR2Form 8-K - Current report
08/11/202412:00BWAmneal Reports Third Quarter 2024 Financial Results
31/10/202423:51EDGAR2Form SC 13D/A - General Statement of Acquisition of..
21/10/202414:00BWAmneal Receives U.S. FDA Approval of New Drug Application..
08/10/202422:05BWAmneal to Report Third Quarter 2024 Results on November 8,..
01/10/202413:10EDGAR2Form 8-K - Current report
01/10/202412:00BWAmneal and Metsera Announce Strategic Collaboration to..
16/8/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202422:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202412:14EDGAR2Form 8-K - Current report
20/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202421:13EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:15EDGAR2Form SC 13D/A - General statement of acquisition of..
08/5/202422:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apertura: 8,75 Min: 8,61 Max: 8,85
Chiusura: 8,97

La tua Cronologia

NASDAQ
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci